GO:0097157 pre-mRNA intronic binding: RNA Splicing Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097157 pre-mRNA intronic binding describes the molecular function of selectively binding to intronic sequences within a pre-mRNA transcript, a prerequisite for splice site recognition and spliceosome assembly.
• Intronic binding is mediated by RNA-binding proteins such as hnRNP C, HP1γ, and NONO, which recognize sequence motifs, repeats, or structural elements within introns.
• The process is essential for both constitutive and alternative splicing, and its disruption causes aberrant exon inclusion, intron retention, and transcriptome instability.
• Disease-causing sequence changes frequently act by creating or destroying intronic binding sites, making this term central to interpreting genetic variants.
• Antisense oligonucleotides can therapeutically modulate intronic binding to correct splicing defects.
• CRISPR-based knockout, point-mutation, and knock-in models are powerful tools for dissecting the causal role of intronic binding proteins and elements.
Description
GO:0097157 pre-mRNA intronic binding is a Gene Ontology molecular function term that describes the selective interaction of a protein or ribonucleoprotein complex with intronic sequences within a precursor messenger RNA (pre-mRNA) transcript. Introns are the non-coding segments removed during splicing, and their recognition by trans-acting factors is a fundamental step in defining splice sites and assembling the spliceosome. This binding activity is not merely passive; it directly influences splice site selection, exon definition, and the overall fidelity of mRNA maturation. Researchers study pre-mRNA intronic binding because it sits at the intersection of RNA processing, gene regulation, and human disease. Mutations that create or destroy intronic binding motifs are a well-recognized cause of genetic disorders, and aberrant intronic binding by splicing factors contributes to cancer and neurodegeneration. Understanding which proteins bind which intronic elements, and how those interactions are regulated, is therefore essential for interpreting genomic variants and for developing RNA-targeted therapeutics.
pre-mRNA intronic binding At A Glance
| GO ID | GO:0097157 |
|---|---|
| GO term | pre-mRNA intronic binding |
| Ontology | Molecular function |
| Synonym | None listed in QuickGO |
| Major function | Selective binding to intronic sequences or structures within pre-mRNA, enabling splice site recognition and spliceosome assembly |
| Biological context | Constitutive and alternative pre-mRNA splicing |
| Key molecular players | hnRNP C, HP1γ, NONO, and other splicing factors |
| Disease relevance | Genetic variants that alter intronic binding cause splicing defects; aberrant binding contributes to cancer |
| Therapeutic angle | Antisense oligonucleotides can modulate intronic binding to correct splicing |
What Is GO:0097157?
In our own words, GO:0097157 pre-mRNA intronic binding is the molecular function of binding selectively and non-covalently to a sequence or structural element located within an intron of a pre-mRNA molecule. This activity is performed by RNA-binding proteins and ribonucleoprotein complexes that recognize intronic motifs, repeats, or secondary structures, thereby positioning themselves to influence splice site recognition, spliceosome assembly, and alternative splicing decisions.
Why Is pre-mRNA intronic binding Important in Cell Biology?
pre-mRNA intronic binding is important because it determines how the spliceosome interprets the vast non-coding space of a pre-mRNA. Without selective intronic recognition, splice sites cannot be efficiently paired, and the transcriptome would be overwhelmed by aberrant exon inclusion or intron retention. This function is also a major mechanism by which genetic variants cause disease: a single nucleotide change can create or destroy an intronic binding site, leading to mis-splicing. Moreover, splicing factors that bind introns are frequently dysregulated in cancer, where they reprogram alternative splicing to favor tumor progression. Studying GO:0097157 therefore connects basic RNA biology to clinical genetics and oncology.
• Defines splice site recognition and exon definition during spliceosome assembly.
• Controls alternative splicing decisions that expand proteome diversity.
• Explains a large fraction of disease-causing intronic variants.
• Is a mechanism of transcriptome protection against aberrant circularization.
• Contributes to cancer progression through splicing factor dysregulation.
• Provides a target for antisense oligonucleotide therapeutics.
• Is required for normal spliceosome disassembly and recycling.
• Links chromatin-associated proteins such as HP1γ to RNA processing.
• Enables intron retention as a regulated post-transcriptional control mechanism.
• Offers a functional readout for CRISPR-based variant interpretation.
Molecular Mechanism of pre-mRNA intronic binding
Recognition of intronic sequence motifs
In simple terms: Proteins scan the intron for short sequence patterns they can latch onto.
The first step in pre-mRNA intronic binding is the recognition of specific sequence motifs or structural features within the intron. RNA-binding proteins use RNA-recognition motifs and other domains to read the sequence and shape of intronic RNA. For example, hnRNP C binds to inverted Alu elements within introns, a interaction that protects the transcriptome from pre-mRNA circularization. Similarly, HP1γ binds intronic repeats to modulate splicing decisions. This motif recognition is the foundation for all downstream splicing regulation.
Splice site definition and exon bridging
In simple terms: Bound proteins help the splicing machinery decide where to cut.
Once bound to intronic elements, proteins help define the 5' and 3' splice sites by recruiting or blocking core spliceosomal components. Intronic binding proteins can bridge across exons to stabilize exon definition, ensuring that the correct exon is included in the mature mRNA. This step is critical because the spliceosome must distinguish true splice sites from the many cryptic sites present in large introns.
Spliceosome assembly and catalytic activation
In simple terms: The binding event triggers the assembly of the molecular machine that performs splicing.
Intronic binding by factors such as NONO and other splicing proteins facilitates the ordered assembly of the spliceosome on the pre-mRNA. The spliceosome undergoes multiple conformational rearrangements before catalysis, and intronic binding proteins help stabilize these intermediates. Recent structural work has revealed how the spliceosome initiates disassembly after catalysis, a process that also depends on proper intronic interactions.
Regulation by chromatin and antisense oligonucleotides
In simple terms: Other molecules can strengthen or block the binding, changing the splicing outcome.
Intronic binding is not static; it can be modulated by chromatin-associated proteins such as HP1γ, which links histone modifications to splicing decisions. Antisense oligonucleotides can be designed to mask intronic binding sites, thereby redirecting splicing for therapeutic benefit. This regulatory layer makes pre-mRNA intronic binding a dynamic and druggable process.
Quality control and transcriptome stability
In simple terms: Proper binding prevents the RNA from being misprocessed or degraded.
Correct intronic binding is essential for transcriptome stability. When hnRNP C binding to inverted Alu elements is impaired, pre-mRNAs can be aberrantly circularized, highlighting a protective role for intronic binding. Similarly, failure to properly define introns can lead to intron retention and nonsense-mediated decay. Thus, GO:0097157 contributes to quality control of mRNA maturation.
Key Genes Involved in GO:0097157 pre-mRNA intronic binding
The following genes and proteins are experimentally implicated in pre-mRNA intronic binding and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HNRNPC | Binds inverted Alu elements in introns; protects against circularization | Studied for transcriptome stability and splicing regulation |
| HP1γ (CBX3) | Binds intronic repeats and modulates splicing decisions | Links chromatin state to RNA processing |
| NONO | Splicing factor that binds introns and regulates exon inclusion | Target for cancer therapy in glioblastoma |
| SRSF1 | Serine/arginine-rich splicing factor that recognizes intronic enhancers | Model for alternative splicing regulation |
| SRSF2 | Binds intronic splicing enhancers; frequently mutated in myeloid neoplasms | Relevant to cancer splicing reprogramming |
| U2AF1 | Recognizes 3' splice site and adjacent intronic sequences | Core spliceosome component |
| U2AF2 | Binds polypyrimidine tract within introns | Essential for spliceosome assembly |
| SF1 | Binds branch point sequence in introns | Early spliceosome assembly factor |
| PTBP1 | Polypyrimidine tract-binding protein; represses or enhances exon inclusion | Model for neuronal splicing regulation |
| RBFOX1 | Binds intronic UGCAUG elements to regulate neuronal splicing | Implicated in neurodevelopmental disorders |
| TIA1 | Binds U-rich intronic sequences; regulates stress granule and splicing | Links RNA binding to stress responses |
| HNRNPA1 | Binds intronic splicing silencers | Model for hnRNP-mediated splicing repression |
| RBM39 | Binds introns and regulates splicing; target of anticancer sulfonamides | Therapeutic relevance in cancer |
| PRPF8 | Core spliceosome protein that interacts with intronic sequences | Structural studies of spliceosome |
| SNRNP200 | RNA helicase that rearranges intronic RNA during splicing | Required for spliceosome activation |
| DDX5 | RNA helicase that binds introns and modulates splicing | Involved in transcription-splicing coupling |
| DHX9 | Binds intronic repeats and regulates RNA processing | Relevant to genome stability |
How Is pre-mRNA intronic binding Regulated?
pre-mRNA intronic binding is regulated at multiple levels. Chromatin-associated proteins such as HP1γ can bind intronic repeats and influence splicing decisions, coupling transcription with RNA processing. The abundance and post-translational modification of splicing factors also control intronic binding; for example, phosphorylation of SR proteins modulates their interactions with intronic enhancers. Antisense oligonucleotides can be used experimentally to block or enhance intronic binding, providing a tool to dissect regulatory mechanisms. Additionally, the spliceosome cycle itself is regulated by ATP-dependent helicases that rearrange intronic RNA during assembly and disassembly.
pre-mRNA intronic binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NONO | Glioblastoma progression via GPX1 intron retention | Knockout or knockdown in GBM cell lines |
| HNRNPC | Transcriptome instability and circular RNA accumulation | Knockout in HEK293 or cancer cells |
| HP1γ (CBX3) | Splicing decisions linked to chromatin state | Point mutation of binding domain |
| SRSF2 | Myeloid neoplasms with splicing factor mutations | Knock-in of disease-associated mutation |
| U2AF1 | Myelodysplastic syndromes | Knock-in of S34F mutation |
Genetic disorders caused by intronic variants
Many disease-causing sequence changes act by creating or destroying intronic binding sites, leading to aberrant splicing. For example, mutations that alter intronic splicing enhancers or silencers can cause exon skipping or inclusion, resulting in inherited disorders. Understanding pre-mRNA intronic binding is therefore essential for interpreting genetic variants identified in clinical sequencing.
Cancer and splicing factor dysregulation
Splicing factors that bind introns are frequently overexpressed or mutated in cancer. NONO, for instance, binds introns and promotes glioblastoma progression through GPX1 intron retention; targeting NONO inhibits tumor growth. Similarly, mutations in SRSF2 and U2AF1 alter intronic binding specificity and drive myeloid malignancies. These findings position pre-mRNA intronic binding as a therapeutic vulnerability in cancer.
Neurodegeneration and RNA processing
Neuronal splicing regulators such as RBFOX1 and PTBP1 bind intronic elements to control synaptic gene expression. Dysregulation of these interactions has been linked to neurodevelopmental and neurodegenerative conditions. The precise role of intronic binding in neuronal disease is an active area of research.
From pre-mRNA intronic binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HNRNPC cause aberrant circularization? | CRISPR knockout of HNRNPC in HEK293 cells |
| Does HP1γ intronic binding modulate specific splicing events? | Point mutation in HP1γ RNA-binding domain |
| Can a disease-associated intronic variant be corrected? | Knock-in of the variant followed by antisense oligonucleotide treatment |
| Does NONO inhibition affect glioblastoma growth? | Knockout or overexpression of NONO in GBM cell lines |
| How does SRSF2 mutation alter intronic binding specificity? | Knock-in of SRSF2 P95H in hematopoietic cells |
| Can intronic binding be visualized in live cells? | Tagged knock-in of splicing factors with fluorescent proteins |
How to Study the pre-mRNA intronic binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CLIP-seq | Genome-wide intronic binding sites of an RNA-binding protein | Mapping hnRNP C or HP1γ binding |
| Minigene assay | Splicing outcome of a specific intronic variant | Testing disease-associated variants |
| Antisense oligonucleotide treatment | Effect of blocking intronic binding on splicing | Therapeutic splicing correction |
| Cryo-EM | Three-dimensional structure of spliceosome-intron complexes | Mechanistic studies of spliceosome assembly |
| RNA-seq | Transcriptome-wide changes in splicing | Knockout or knockdown studies |
| RT-PCR | Specific exon inclusion or intron retention events | Validation of splicing changes |
| CRISPR knockout | Loss-of-function phenotype of intronic binding proteins | Functional studies |
| Knock-in of point mutations | Effect of disease-associated mutations on intronic binding | Modeling genetic disorders |
RNA immunoprecipitation and CLIP-seq
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) is the gold standard for mapping intronic binding sites of RNA-binding proteins at nucleotide resolution. This method identifies the exact intronic sequences bound by proteins such as hnRNP C and HP1γ, providing a genome-wide view of pre-mRNA intronic binding.
Minigene splicing reporters
Minigene reporters containing specific intronic elements are used to test the functional consequence of intronic binding. By mutating predicted binding sites and measuring splicing outcomes, researchers can determine whether a given intronic sequence is necessary for correct splicing.
Antisense oligonucleotide modulation
Antisense oligonucleotides can be designed to block or enhance intronic binding, providing a powerful method to manipulate splicing in vitro and in vivo. This approach is used both to study mechanism and to develop therapeutics for splicing-related diseases.
Structural biology and cryo-EM
Cryo-electron microscopy has revealed how the spliceosome interacts with intronic RNA during assembly and disassembly. These structures provide mechanistic insights into how intronic binding positions splice sites for catalysis.
How CRISPR Can Be Used to Study GO:0097157 pre-mRNA intronic binding
Knockout
CRISPR knockout of genes encoding intronic binding proteins, such as HNRNPC or NONO, allows researchers to assess their loss-of-function phenotypes on splicing and cell viability. Knockout cell lines are essential for determining whether a candidate gene is causally involved in pre-mRNA intronic binding.
Point Mutation
Point mutations in the RNA-binding domains of splicing factors can be introduced using CRISPR base editing or homology-directed repair to dissect the contribution of specific residues to intronic binding. This approach is particularly useful for modeling disease-associated mutations in SRSF2 or U2AF1.
Knock-in
Knock-in of disease-associated intronic variants or splicing factor mutations enables the study of their effects on pre-mRNA intronic binding in a physiological context. For example, knocking in a mutation that creates a novel intronic binding site can reveal its impact on splicing.
Overexpression
Overexpression of intronic binding proteins, such as HP1γ or NONO, can be achieved by CRISPR activation or lentiviral delivery to study gain-of-function effects on splicing and disease progression. Overexpression models are valuable for identifying downstream targets and therapeutic vulnerabilities.
How EDITGENE Supports pre-mRNA intronic binding Research
Researchers studying pre-mRNA intronic binding-related genes often need to determine whether a candidate gene is causally involved in splicing regulation or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for pre-mRNA intronic binding research.
Frequently Asked Questions About pre-mRNA intronic binding
What is pre-mRNA intronic binding?
pre-mRNA intronic binding (GO:0097157) is the molecular function of selectively binding to intronic sequences within a pre-mRNA transcript, a key step in splice site recognition and spliceosome assembly.
What genes are involved in pre-mRNA intronic binding?
Genes such as HNRNPC, HP1γ (CBX3), NONO, SRSF1, SRSF2, U2AF1, and PTBP1 encode proteins that bind intronic elements and regulate splicing.
How does pre-mRNA intronic binding affect splicing?
It helps define splice sites, recruit spliceosomal components, and determine whether an exon is included or skipped, thereby controlling alternative splicing.
What diseases are associated with defects in pre-mRNA intronic binding?
Defects can cause genetic disorders through mis-splicing and are implicated in cancers such as glioblastoma and myeloid neoplasms.
Can antisense oligonucleotides modulate pre-mRNA intronic binding?
Yes, antisense oligonucleotides can block or enhance intronic binding sites to correct splicing defects, and this approach is under therapeutic development.
What methods are used to study pre-mRNA intronic binding?
Common methods include CLIP-seq, minigene assays, antisense oligonucleotide treatment, cryo-EM, RNA-seq, and CRISPR-based knockout or knock-in models.
What is the role of hnRNP C in pre-mRNA intronic binding?
hnRNP C binds inverted Alu elements in introns and protects the transcriptome from aberrant pre-mRNA circularization.
How does HP1γ regulate pre-mRNA intronic binding?
HP1γ binds intronic repeats and modulates splicing decisions, linking chromatin state to RNA processing.
Is pre-mRNA intronic binding a drug target?
Yes, splicing factors that bind introns, such as NONO, are being explored as therapeutic targets in cancer.
How can CRISPR help study pre-mRNA intronic binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of intronic binding proteins and elements in splicing and disease.
Conclusion
GO:0097157 pre-mRNA intronic binding is a fundamental molecular function that governs how introns are recognized and processed during splicing. Its dysregulation underlies a wide range of genetic disorders and cancers, making it a critical area of research. By combining CRISPR-based models with advanced RNA methodologies, researchers can dissect the mechanisms and therapeutic potential of intronic binding. EDITGENE offers the tools and expertise to accelerate these discoveries.
References
- 1. Baralle D et al.. 2005. Splicing in action: assessing disease causing sequence changes.. J Med Genet 42(10):737-48 PMID: 16199547
- 2. Wilkinson ME et al.. 2020. RNA Splicing by the Spliceosome.. Annu Rev Biochem 89:359-388 PMID: 31794245
- 3. Rachez C et al.. 2021. HP1γ binding pre-mRNA intronic repeats modulates RNA splicing decisions.. EMBO Rep 22(9):e52320 PMID: 34312949
- 4. Black DL. 2003. Mechanisms of alternative pre-messenger RNA splicing.. Annu Rev Biochem 72:291-336 PMID: 12626338
- 5. Vorländer MK et al.. 2024. Mechanism for the initiation of spliceosome disassembly.. Nature 632(8024):443-450 PMID: 38925148
- 6. Wang X et al.. 2022. Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention.. Theranostics 12(12):5451-5469 PMID: 35910786
- 7. Singh NN et al.. 2025. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.. Methods Mol Biol 2964:381-404 PMID: 40720032
- 8. Marini A et al.. 2026. HnRNP C binding to inverted Alu elements protects the transcriptome from pre-mRNA circularization.. Sci Adv 12(18):eaea2351 PMID: 42066070
